News
Clinical trial data review on weight-loss drugs reveals weight regain patterns post-medication discontinuation, impacting weight management strategies.
3h
HealthDay on MSNRisk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, ObesityFor adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a ...
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
Experts reveal how Mounjaro actually works on your body after people took to social media complaining over 'hair loss' side ...
Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.
Drugs like Ozempic and Mounjaro are becoming increasingly popular for treating obesity and type 2 diabetes. These medications ...
Explore more
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...
India is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expirations of blockbuster drugs. Pharmaceutical giants are ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...
Two drugs commonly known as Mounjaro and Trulicity, will not be available for online sale to non-Canadian residents.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results